gdc

Leukemia

Treatment of Chronic Lymphocytic Leukemia During the COVID-19 Pandemic
CLL Monthly MinutesLeukemia
The COVID-19 pandemic has resulted in several changes in how patients with chronic lymphocytic leukemia (CLL) are treated.
From Watchful Waiting to Early Treatment of Asymptomatic Chronic Lymphocytic Leukemia
CLL Monthly MinutesLeukemia
Better identification of patients at high risk of disease progression and newer treatments may mean that fewer newly diagnosed patients must “watch and wait.”
Using Telemedicine to Protect Vulnerable Patients and Provide Access to Care During COVID-19
CLL Monthly MinutesLeukemia
The use of telemedicine has shown rapid growth over the course of the pandemic, with some experts suggesting that it is here to stay.
Studying the Effects of a “Can-Do” Attitude on Cancer Outcomes
CLL Monthly MinutesLeukemia
Can a digital coach improve health outcomes in patients with blood cancers? An ongoing clinical trial should provide insights.
Lenalidomide Maintenance Therapy Linked to B-Cell Acute Lymphoblastic Leukemia
CLL Monthly MinutesLeukemia
Three patients with chronic lymphocytic leukemia were found to have progression to B-ALL after treatment with lenalidomide causing early termination of a clinical study.
A Look at COVID-19 Vaccination in Patients with Chronic Lymphocytic Leukemia
CLL Monthly MinutesLeukemia
It is recommended that most patients with CLL receive the COVID-19 vaccine, although each patient should still talk with their healthcare team first.
Predicting Which Patients with Chronic Lymphocytic Leukemia Might Need Early Treatment
CLL Monthly MinutesLeukemia
A new laboratory-based scoring system may allow physicians to better predict which patients with early-stage CLL are most likely to require early treatment.
Evaluating the Risk of Severe COVID-19 in Patients with Chronic Lymphocytic Leukemia
CLL Monthly MinutesLeukemia
Patients with CLL may be at increased risk for developing severe COVID-19. Experts have provided insights on how to protect them while still delivering optimal care.
Zanubrutinib Now Recommended for Certain Patients with Chronic Lymphocytic Leukemia
CLL Monthly MinutesLeukemia
Updated National Comprehensive Cancer Network (NCCN) guidelines now recommend zanubrutinib as alternative first- and second-line therapy for some patients.
A Look at Cannabis Extracts for Patients with Chronic Lymphocytic Leukemia
CLL Monthly MinutesLeukemia
Cannabis compounds such as cannabidiol have shown cancer-fighting activity in the lab. What should patients know?
Page 1 of 10
Results 1 - 10 of 99

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country